Risperdal® Consta®

DRUG2 trials

Sponsors

Luye Pharma Group Ltd.

Conditions

Schizoaffective DisorderSchizophrenia

Phase 1

Bioavailability of LY03004 and Risperdal® Consta®

CompletedNCT02091388

Luye Pharma Group Ltd.Schizoaffective Disorder, Schizophrenia

Start: 2014-09-30End: 2015-01-31Updated: 2015-03-04

An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder

CompletedNCT02186769

Luye Pharma Group Ltd.Schizoaffective Disorder, Schizophrenia

Start: 2014-07-31End: 2015-04-30Updated: 2015-06-18

Related Papers

Population Pharmacokinetic Analysis to Support and Facilitate Switching from Risperidone Formulations to Rykindo in Patients with Schizophrenia

Neurology and Therapy2024-01-204 citations